These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 20145274)

  • 1. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
    Brault L; Gasser C; Bracher F; Huber K; Knapp S; Schwaller J
    Haematologica; 2010 Jun; 95(6):1004-15. PubMed ID: 20145274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
    Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
    Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PIM kinases in hematological cancers.
    Alvarado Y; Giles FJ; Swords RT
    Expert Rev Hematol; 2012 Feb; 5(1):81-96. PubMed ID: 22272708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
    Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
    Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets.
    Saurabh K; Scherzer MT; Shah PP; Mims AS; Lockwood WW; Kraft AS; Beverly LJ
    Oncotarget; 2014 Sep; 5(18):8503-14. PubMed ID: 25238262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIM kinases: an overview in tumors and recent advances in pancreatic cancer.
    Xu J; Zhang T; Wang T; You L; Zhao Y
    Future Oncol; 2014 Apr; 10(5):865-76. PubMed ID: 24799066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Quinoxaline Derivatives as Dual Pim-1/2 Kinase Inhibitors: Design, Synthesis and Biological Evaluation.
    Oyallon B; Brachet-Botineau M; Logé C; Robert T; Bach S; Ibrahim S; Raoul W; Croix C; Berthelot P; Guillon J; Pinaud N; Gouilleux F; Viaud-Massuard MC; Denevault-Sabourin C
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33562106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
    Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
    PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
    Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
    Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Pim kinases in hematological cancers: molecular and clinical review.
    Bellon M; Nicot C
    Mol Cancer; 2023 Jan; 22(1):18. PubMed ID: 36694243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PIM family of serine/threonine kinases in cancer.
    Narlik-Grassow M; Blanco-Aparicio C; Carnero A
    Med Res Rev; 2014 Jan; 34(1):136-59. PubMed ID: 23576269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review on structure-function mechanism and signaling pathway of serine/threonine protein PIM kinases as a therapeutic target.
    Rout AK; Dehury B; Parida SN; Rout SS; Jena R; Kaushik N; Kaushik NK; Pradhan SK; Sahoo CR; Singh AK; Arya M; Behera BK
    Int J Biol Macromol; 2024 Jun; 270(Pt 1):132030. PubMed ID: 38704069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIM kinases as therapeutic targets against advanced melanoma.
    Shannan B; Watters A; Chen Q; Mollin S; Dörr M; Meggers E; Xu X; Gimotty PA; Perego M; Li L; Benci J; Krepler C; Brafford P; Zhang J; Wei Z; Zhang G; Liu Q; Yin X; Nathanson KL; Herlyn M; Vultur A
    Oncotarget; 2016 Aug; 7(34):54897-54912. PubMed ID: 27448973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pim kinases in hematological malignancies: where are we now and where are we going?
    Mondello P; Cuzzocrea S; Mian M
    J Hematol Oncol; 2014 Dec; 7():95. PubMed ID: 25491234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of PIM1/PIM2 kinases in tumors of the male reproductive system.
    Jiménez-García MP; Lucena-Cacace A; Robles-Frías MJ; Narlik-Grassow M; Blanco-Aparicio C; Carnero A
    Sci Rep; 2016 Nov; 6():38079. PubMed ID: 27901106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002.
    Jacobs MD; Black J; Futer O; Swenson L; Hare B; Fleming M; Saxena K
    J Biol Chem; 2005 Apr; 280(14):13728-34. PubMed ID: 15657054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
    Brault L; Menter T; Obermann EC; Knapp S; Thommen S; Schwaller J; Tzankov A
    Br J Cancer; 2012 Jul; 107(3):491-500. PubMed ID: 22722314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of regulators and inhibitors of Pim-1, a serine/threonine kinase, for tumour therapy (review).
    Liang C; Li YY
    Mol Med Rep; 2014 Jun; 9(6):2051-60. PubMed ID: 24737044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
    Kreuz S; Holmes KB; Tooze RM; Lefevre PF
    Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma.
    Schatz JH; Oricchio E; Wolfe AL; Jiang M; Linkov I; Maragulia J; Shi W; Zhang Z; Rajasekhar VK; Pagano NC; Porco JA; Teruya-Feldstein J; Rosen N; Zelenetz AD; Pelletier J; Wendel HG
    J Exp Med; 2011 Aug; 208(9):1799-807. PubMed ID: 21859846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.